Special Issue "Emerging Pain Targets and Therapy"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 July 2012)
Dr. Kim Lawson (Website)
Department of Biosciences and Chemistry, Biomolecular Sciences Research Centre, Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK
Interests: fibromyalgia; pain; potassium channels; drug design/discovery
Pain remains a major clinical challenge with the management of pain the most frequent issue encountered by clinicians. Many current analgesics are limited by serious unwanted effects, while for some pain conditions there are no effective analgesics. Advances in molecular biological techniques that have enabled the discovery of specific molecules involved in pain production have contributed to a better understanding of pain and the mechanisms of different types of pain and are providing clues for the development of novel pharmacotherapies for specific pain types. This increased understanding of pain physiology has offered a number of potential targets (e.g. TRPV1, voltage-gated sodium channels, calcium channels, glutamate receptors, cannabinoids) for future treatments, in particular for neuropathic and chronic pain. This special issue is intended to provide the reader with an insight into the progress made in this field through novel contributions of original papers and critical reviews.
Dr. Kim Lawson
- pain pathways
- emerging targets
- molecular biology
- novel therapies
- ion channels